Clearside Biomedical Inc (NASDAQ:CLSD) Short Interest Reduced By 44.68%

April 16, 2018 - By Daniel Mitchell

It was noted a decrease on Clearside Biomedical Inc (NASDAQ:CLSD)’s shares shorted with 44.68%. FINRA announced in April CLSD’s total 847,800 shares shorted. That’s 44.68% down from 1.53M shares. Former CLSD’s position will need 6 days to restore. It has 148,900 average volume. 4.6% is Clearside Biomedical Inc float short.

Its shares touched $10.16 on during the last trading session after 3.88% change.Clearside Biomedical, Inc. has volume of 160,743 shares. Since April 16, 2017 CLSD has risen 41.83% and is uptrending. CLSD outperformed the S&P 500 by 30.28%.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye.The firm is worth $324.24 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion ; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME).Currently it has negative earnings. The companyÂ’s pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD).

Clearside Biomedical, Inc. (NASDAQ:CLSD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: